

# SALMONELLA VECTOR

●●● Licensing opportunity L-12259

## HIGHLIGHTS

Promising approaches for delivering antigens and generating a protective response against cancers and infectious diseases currently employ existing vaccine strain bacteria or closely-related attenuated bacteria. Human clinical trials have shown excellent safety profiles with various recombinant vaccine strain bacteria, but generally poor efficacies for promoting immunity against the targeted diseases. Finding the right vaccine vector and antigen production system to rapidly induce an immune response while causing minimal toxicity has been challenging. To address this problem, the NRC has developed a recombinant attenuated *Salmonella* vaccine system capable of producing rapid cell-mediated immune protection against infectious diseases and cancers.

## TECHNOLOGY TRANSFER


- Commercial exploitation license
- R&D agreement for development

## MARKET APPLICATIONS

- Delivery vector for vaccines against infectious diseases or cancer

## HOW IT WORKS

*Salmonella* is an invasive bacterium that resides in phagosomes of infected cells; it is able to avoid immune detection and induce chronic infection. Mutants of *Salmonella typhimurium* have been considered for developing oral vaccine delivery systems using the recombinant expression of disease-associated antigens. However, vaccination with



Antigen secretion from invasive *Salmonella* stimulates a T cell response (IFN $\gamma$  secretion) targeting the antigen. The viral antigen tested here is Lymphocytic Choriomeningitis Virus NP protein.

attenuated *Salmonella* is associated with several problems, including failure to activate rapid T cell production, poor immune stimulation with over-attenuated strains, and immune suppression.

To address these problems, the NRC-HHT has built upon research making use of a bacterial Type III secretion system to deliver foreign antigens from the bacteria into the host cell cytosol. Processing of the foreign antigens from the cytosol of infected antigen-presenting cells enables a good induction of T cell immunity. Further refinements of this system involve the augmentation of inflammation and reduction of immune suppression induced by the attenuated *Salmonella* through the introduction of immunomodulators along with the foreign antigen expression cassette.

Preclinical studies conducted in mice have shown that the vector is efficacious in inducing a rapid immune response against test antigens from lymphocytic choriomeningitis virus and melanoma.

## BENEFITS

- Ideal for oral vaccine administration
- Can be used with a wide range of antigens
- Rapid, persistent cellular immune response

## PATENTS

NRC file 12259: Patents issued in the United States and Europe; pending in Canada.

## CONTACT

**Alexandre Serrano**  
Client Relationship Leader  
514-496-6211  
Alexandre.Serrano@cnrc-nrc.gc.ca

[www.canada.ca/nrc-human-health-therapeutics](http://www.canada.ca/nrc-human-health-therapeutics)

© 2019 Her Majesty the Queen in Right of Canada, as represented by the National Research Council of Canada.

Paper: Cat. No. NR16-176/2017E  
ISBN 978-0-660-23968-2  
PDF: Cat. No. NR16-176/2017E-PDF  
ISBN 978-0-660-23967-5

June 2019

**NRC.CANADA.CA** •